Afuco™ Anti-Human APCS ADCC Therapeutic Antibody, ADCC Enhanced
Anti-APCS ADCC Enhanced Antibody is an ADCC enhanced antibody produced by our Afuco™ platform. Anti-SAP antibody treatment is clinically feasible because circulating human SAP can be depleted in patients by the bis-D-proline compound, CPHPC4, thereby enabling injected anti-SAP antibodies to reach residual SAP in the amyloid deposits. The unprecedented capacity of this novel combined therapy to eliminate amyloid deposits should be applicable to all forms of systemic and local amyloidosis.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-045CL |
| Pricing | Inquiry |
| Host | Human |
| Target | APCS |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | ≤1 year at -20°C. |